[go: up one dir, main page]

ZA202305698B - Stable coronavirus proteins and vaccine compositions thereof - Google Patents

Stable coronavirus proteins and vaccine compositions thereof

Info

Publication number
ZA202305698B
ZA202305698B ZA2023/05698A ZA202305698A ZA202305698B ZA 202305698 B ZA202305698 B ZA 202305698B ZA 2023/05698 A ZA2023/05698 A ZA 2023/05698A ZA 202305698 A ZA202305698 A ZA 202305698A ZA 202305698 B ZA202305698 B ZA 202305698B
Authority
ZA
South Africa
Prior art keywords
stable
coronavirus
vaccine compositions
proteins
mutated
Prior art date
Application number
ZA2023/05698A
Other languages
English (en)
Inventor
Daniel Ellis
Neil King
Jesse Bloom
Tyler Starr
Allison Greaney
Original Assignee
Univ Washington
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Hutchinson Fred Cancer Res filed Critical Univ Washington
Publication of ZA202305698B publication Critical patent/ZA202305698B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2023/05698A 2020-12-31 2023-05-26 Stable coronavirus proteins and vaccine compositions thereof ZA202305698B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063132863P 2020-12-31 2020-12-31
US202163188651P 2021-05-14 2021-05-14
PCT/US2021/037341 WO2022146484A1 (fr) 2020-12-31 2021-06-15 Protéines de coronavirus stables et compositions de vaccin associées

Publications (1)

Publication Number Publication Date
ZA202305698B true ZA202305698B (en) 2024-12-18

Family

ID=82260758

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/05698A ZA202305698B (en) 2020-12-31 2023-05-26 Stable coronavirus proteins and vaccine compositions thereof

Country Status (11)

Country Link
EP (1) EP4271698A4 (fr)
JP (1) JP2024502823A (fr)
KR (1) KR20230135598A (fr)
AU (1) AU2021415906A1 (fr)
BR (1) BR112023013138A2 (fr)
CA (1) CA3201697A1 (fr)
CL (2) CL2023001930A1 (fr)
CO (1) CO2023008898A2 (fr)
PE (1) PE20241316A1 (fr)
WO (1) WO2022146484A1 (fr)
ZA (1) ZA202305698B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024130083A1 (fr) * 2022-12-15 2024-06-20 Mayo Foundation For Medical Education And Research Virus de rougeole modifiés pour le traitement d'infections à coronavirus
WO2024238311A1 (fr) * 2023-05-12 2024-11-21 Icosavax, Inc. Domaines de liaison au récepteur de glycoprotéine de spicule du coronavirus et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210124272A (ko) * 2019-02-08 2021-10-14 더 유에스에이, 애즈 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬스 앤드 휴먼 서비스 나노입자-기반 인플루엔자 바이러스 백신 및 이의 용도
WO2021252688A1 (fr) * 2020-06-09 2021-12-16 Icosavax, Inc. Procédé d'assemblage de particules de type viral à deux constituants
WO2022003719A2 (fr) * 2020-07-03 2022-01-06 Indian Institute Of Science Fragments polypeptidiques, composition immunogène contre le sras-cov-2 et mise en oeuvre de ceux-ci
CN112076315B (zh) * 2020-08-25 2023-09-01 中国农业科学院生物技术研究所 新冠病毒s蛋白和铁蛋白亚基融合的纳米抗原颗粒、新冠疫苗及其制备方法和应用
CN113150084B (zh) * 2021-03-23 2023-03-21 江苏坤力生物制药有限责任公司 一种纳米化的冠状病毒抗原及其应用

Also Published As

Publication number Publication date
CO2023008898A2 (es) 2023-09-29
JP2024502823A (ja) 2024-01-23
PE20241316A1 (es) 2024-06-26
EP4271698A1 (fr) 2023-11-08
AU2021415906A1 (en) 2023-07-06
EP4271698A4 (fr) 2025-05-21
CL2023001930A1 (es) 2023-11-24
BR112023013138A2 (pt) 2023-10-31
CL2025000561A1 (es) 2025-04-21
KR20230135598A (ko) 2023-09-25
CA3201697A1 (fr) 2022-07-07
WO2022146484A1 (fr) 2022-07-07

Similar Documents

Publication Publication Date Title
ZA202305698B (en) Stable coronavirus proteins and vaccine compositions thereof
MX2022015040A (es) Proteina espicular (s) del coronavirus geneticamente manipulada y metodos de uso de la misma.
WO2021062281A3 (fr) Cellules effectrices à ciblage multiple et leur utilisation
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
MX2022001134A (es) Proteinas quimericas de factor viii y usos de estas.
BR112022006440A2 (pt) Receptor de antígeno quimérico intensificado para manipulação de célula efetora imune e uso do mesmo
MY193354A (en) Anti-vegf protein compositions and methods for producing the same
WO2021216743A3 (fr) Vaccins contre le coronavirus,, compositions et procédés associés
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
CY1118167T1 (el) Πρωτογενη και εγγυς ηπατικα βλαστοκυτταρα
WO2015023891A3 (fr) Fusions de facteur vii-xten et leurs utilisations
BR112022000545A2 (pt) Composições de proteína e produtos de consumo destas
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
MX2024010472A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
ATE339963T1 (de) Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung
WO2007055823A3 (fr) Lignees cellulaires et anticorps exprimant le gpcr
ATE472334T1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
AR118536A1 (es) Composiciones y métodos para estabilizar formulaciones que contienen proteína
WO2022103929A3 (fr) Acides nucléiques, protéines et vaccins contre le sars-cov-2
ATE286139T1 (de) Replikationskompetente anti-tumor vektoren
MX2023002413A (es) Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados.
PH12017502080A1 (en) Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
WO2023280220A9 (fr) Variant de protéine s du coronavirus et son utilisation
MX2021013702A (es) Subunidad s2 modificada de la proteina de espicula de coronavirus.
EA202092065A1 (ru) ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA)